145 related articles for article (PubMed ID: 36920267)
1. The natural origins of cytostatic compounds used in rhabdomyosarcoma therapy.
Lewandowski D; Szewczyk A; Radzka J; Dubińska-Magiera M; Kazimierczak W; Daczewska M; Migocka-Patrzałek M
Adv Clin Exp Med; 2023 Oct; 32(10):1179-1191. PubMed ID: 36920267
[TBL] [Abstract][Full Text] [Related]
2. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
3. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
4. Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases.
Mentzel T; Kuhnen C
Virchows Arch; 2006 Nov; 449(5):554-60. PubMed ID: 17013628
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience.
Rekhi B; Gupta C; Chinnaswamy G; Qureshi S; Vora T; Khanna N; Laskar S
Ann Diagn Pathol; 2018 Oct; 36():50-60. PubMed ID: 30098515
[TBL] [Abstract][Full Text] [Related]
6. [Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignant mesenchymal tumors of soft tissues].
Mentzel T
Pathologe; 2010 Mar; 31(2):91-6. PubMed ID: 19997735
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyosarcoma: Updates on classification and the necessity of molecular testing beyond immunohistochemistry.
Dehner CA; Rudzinski ER; Davis JL
Hum Pathol; 2024 May; 147():72-81. PubMed ID: 38135061
[TBL] [Abstract][Full Text] [Related]
8. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
[TBL] [Abstract][Full Text] [Related]
9. Anaplasia in childhood rhabdomyosarcoma: An under reported entity.
Ahuja M; Tomar R; Thakur S; Mallya V; Mandal S; Khurana N; Sarin YK
Indian J Pathol Microbiol; 2022; 65(4):864-868. PubMed ID: 36308195
[TBL] [Abstract][Full Text] [Related]
10. Histopathological, immunohistochemical and molecular cytogenetic analysis of 21 spindle cell/sclerosing rhabdomyosarcomas.
Rekhi B; Singhvi T
APMIS; 2014 Nov; 122(11):1144-52. PubMed ID: 24730567
[TBL] [Abstract][Full Text] [Related]
11. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
[TBL] [Abstract][Full Text] [Related]
12. Pediatric soft tissue sarcomas.
Loeb DM; Thornton K; Shokek O
Surg Clin North Am; 2008 Jun; 88(3):615-27, vii. PubMed ID: 18514702
[TBL] [Abstract][Full Text] [Related]
13. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
Yu L; Wang J
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
[TBL] [Abstract][Full Text] [Related]
14. A new marker for rhabdomyosarcoma. Insulin-like growth factor II.
Yun K
Lab Invest; 1992 Nov; 67(5):653-64. PubMed ID: 1434543
[TBL] [Abstract][Full Text] [Related]
15. Rhabdomyosarcoma and soft tissue sarcoma in childhood.
Womer RB; Pressey JG
Curr Opin Oncol; 2000 Jul; 12(4):337-44. PubMed ID: 10888419
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of impaired differentiation in rhabdomyosarcoma.
Keller C; Guttridge DC
FEBS J; 2013 Sep; 280(17):4323-34. PubMed ID: 23822136
[TBL] [Abstract][Full Text] [Related]
17. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for pediatric soft-tissue sarcomas.
Casanova M; Ferrari A
Expert Opin Pharmacother; 2011 Mar; 12(4):517-31. PubMed ID: 21306288
[TBL] [Abstract][Full Text] [Related]
19. An Integrative Morphologic and Molecular Approach for Diagnosis and Subclassification of Rhabdomyosarcoma.
Fan R; Parham DM; Wang LL
Arch Pathol Lab Med; 2022 Aug; 146(8):953-959. PubMed ID: 35051261
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the Diagnosis of Pediatric Spindle Cell/Sclerosing Rhabdomyosarcoma.
Chen S; Rudzinski ER; Arnold MA
Surg Pathol Clin; 2020 Dec; 13(4):729-738. PubMed ID: 33183730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
